Download MendeleyACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker.
Chen, Y., Zhang, Y.N., Yan, R., Wang, G., Zhang, Y., Zhang, Z.R., Li, Y., Ou, J., Chu, W., Liang, Z., Wang, Y., Chen, Y.L., Chen, G., Wang, Q., Zhou, Q., Zhang, B., Wang, C.(2021) Signal Transduct Target Ther 6: 315-315
- PubMed: 34433803
- DOI: https://doi.org/10.1038/s41392-021-00740-y
- Primary Citation of Related Structures:
7V61 - PubMed Abstract:
The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after. Here we report a human angiotensin-converting enzyme 2 (ACE2)-targeting monoclonal antibody, 3E8, blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2, SARS-CoV-2 mutant variants (SARS-CoV-2-D614G, B.1.1.7, B.1.351, B.1.617.1, and P.1), SARS-CoV and HCoV-NL63, without markedly affecting the physiological activities of ACE2 or causing severe toxicity in ACE2 "knock-in" mice. 3E8 also blocked live SARS-CoV-2 infection in vitro and in a prophylactic mouse model of COVID-19. Cryo-EM and "alanine walk" studies revealed the key binding residues on ACE2 interacting with the CDR3 domain of 3E8 heavy chain. Although full evaluation of safety in non-human primates is necessary before clinical development of 3E8, we provided a potentially potent and "broad-spectrum" management strategy against all coronaviruses that utilize ACE2 as entry receptors and disclosed an anti-coronavirus epitope on human ACE2.
Organizational Affiliation:
Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
